Updates are available Correction dated 2020-10-21
Click to view Correction: https://doi.org/10.1007/s40273-020-00968-6
-
Authors
Kim, David D. http://orcid.org/0000-0002-3383-8972
Silver, Madison C.
Kunst, Natalia
Cohen, Joshua T.
Ollendorf, Daniel A.
Neumann, Peter J.
-
Funding
Funding for this research was provided by:
Pharmaceutical Research and Manufacturers of America Foundation (Center of Excellence in Value Assessment Award)
- License Information
-
More Information
Article History
First Online: 20 October 2020
Change Date: 21 October 2020
Change Type: Correction
Change Details: The article Perspective and��Costing in��Cost-Effectiveness Analysis.
Compliance with ethical standards
:
: DDK, MCS, JTC, DAO, and PJN are employees of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, which maintains the CEA Registry and the GHCEA registry used as data sources for this study. The CEA registry is supported by subscription revenue from pharmaceutical and device companies, academic institutions, and government agencies. The GHCEA registry is supported by a grant from the Bill and Melinda Gates Foundation. NK was funded by the Research Council of Norway and LINK Medical Research (grant numbers 276146 and 304034) and has received personal fees for speaking from Thermo Fisher Scientific, outside of the submitted work. JTC has received grants for work conducted on behalf of Amgen, Biogen, and Janssen Pharmaceuticals and has lectured on the use of simulation for Pfizer. JTC has also consulted for AbbVie, Precision Health Economics, Sage Therapeutics, and Sarepta, outside of the submitted work. PJN has held one-time roles on the advisory boards on health economics topics for Avexis, AbbVie, Research Triangle Institute, Merck, Genentech, Bluebird Bio, and Novo Nordisk. PJN serves on the advisory board for the Congressional Budget Office and has consulted for Precision Health Economics, outside of the submitted work.
